Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ZETIA ® is indicated: In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). FDA label
Also known as Ezetimibe, ZETIA, VYTORIN, SCH 465981, Lipitor, Crestor, Ezetrol, MK-0653
SCH 58235 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | ACTIVE_COMPARATOR | SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3) |
| Group B | ACTIVE_COMPARATOR | SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3) |
| Group C | ACTIVE_COMPARATOR | Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3) |
| Group D | ACTIVE_COMPARATOR | Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3) |
| Group E | ACTIVE_COMPARATOR | Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3) |
| Group F | ACTIVE_COMPARATOR | Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3) |
| Name | Type | Description |
|---|---|---|
| SCH 58235 | DRUG | SCH 58235 10 mg (once daily) |
| pitavastatin | DRUG | Pitavastatin 2 mg (once daily) |
Inclusion Criteria: * Healthy adult male subjects meeting all the criteria below or adult male subjects having no obvious disease other than high cholesterol levels. * Aged 20 years or over and 65 years or below when the informed consent is obtained. * Weighing 50 kg or over and 80 kg or below on t...
Top 12 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 4 | PHASE3 | Enlicitide |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Inclisiran, Pelacarsen, DII235, QCZ484 |
| AstraZeneca PLC | AZN | 3 | PHASE3 | AZD0780, Laroprovstat, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5 | PHASE3 | Plozasiran, zodasiran, VSA003 |
| Ionis Pharmaceuticals, Inc. | IONS | 2 | PHASE3 | Olezarsen, ION775 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| Verve Therapeutics, Inc. | VERV | 4 | PHASE2 | VERVE-102, VERVE-201 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
SCH 58235 is a small molecule being developed for hypercholesterolemia, a condition of high cholesterol levels in the blood. It is in Phase 1 clinical development and is being studied in the metabolic therapeutic area.
SCH 58235 is being developed by Organon & Co., a company listed on the stock exchange under the ticker OGN. The drug is in Phase 1 clinical development for hypercholesterolemia.
SCH 58235 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed for the drug.
SCH 58235 has one completed clinical trial, identified as NCT00653913. This Phase 1 study evaluated the potential for drug interaction between SCH 58235 (ezetimibe) and pitavastatin in 18 male participants with hypercholesterolemia.
SCH 58235 is also known as ezetimibe. The completed clinical trial NCT00653913 refers to SCH 58235 as ezetimibe, indicating that these names refer to the same drug.